Concepts (130)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cross Infection | 6 | 2025 | 343 | 2.250 |
Why?
|
| Bacteremia | 4 | 2025 | 428 | 1.550 |
Why?
|
| Central Venous Catheters | 1 | 2025 | 48 | 0.910 |
Why?
|
| Catheterization, Central Venous | 1 | 2025 | 139 | 0.850 |
Why?
|
| Catheter-Related Infections | 1 | 2025 | 137 | 0.830 |
Why?
|
| Sepsis | 3 | 2022 | 515 | 0.710 |
Why?
|
| Middle East Respiratory Syndrome Coronavirus | 1 | 2021 | 22 | 0.700 |
Why?
|
| Burkholderia cepacia complex | 1 | 2017 | 3 | 0.530 |
Why?
|
| Dioctyl Sulfosuccinic Acid | 1 | 2017 | 4 | 0.530 |
Why?
|
| Burkholderia Infections | 1 | 2017 | 8 | 0.530 |
Why?
|
| Drug Contamination | 1 | 2017 | 38 | 0.520 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 570 | 0.480 |
Why?
|
| Pneumonia, Viral | 1 | 2021 | 389 | 0.480 |
Why?
|
| Fellowships and Scholarships | 2 | 2015 | 323 | 0.460 |
Why?
|
| Specialization | 1 | 2015 | 80 | 0.450 |
Why?
|
| Curriculum | 2 | 2015 | 763 | 0.340 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 563 | 0.330 |
Why?
|
| Texas | 7 | 2021 | 3632 | 0.310 |
Why?
|
| Fever of Unknown Origin | 2 | 2016 | 45 | 0.300 |
Why?
|
| Fluconazole | 2 | 2008 | 50 | 0.300 |
Why?
|
| Pediatrics | 2 | 2015 | 1208 | 0.300 |
Why?
|
| Environmental Exposure | 1 | 2011 | 234 | 0.300 |
Why?
|
| Candidiasis | 2 | 2008 | 137 | 0.280 |
Why?
|
| Anti-Bacterial Agents | 4 | 2022 | 2551 | 0.270 |
Why?
|
| Hospitals, Pediatric | 3 | 2021 | 780 | 0.250 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2006 | 70 | 0.230 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2022 | 128 | 0.230 |
Why?
|
| Disease Outbreaks | 3 | 2021 | 329 | 0.230 |
Why?
|
| Child | 9 | 2025 | 25756 | 0.230 |
Why?
|
| Soft Tissue Infections | 1 | 2006 | 91 | 0.220 |
Why?
|
| Fusobacterium | 1 | 2003 | 4 | 0.210 |
Why?
|
| Antifungal Agents | 2 | 2008 | 313 | 0.210 |
Why?
|
| Fusobacterium Infections | 1 | 2003 | 14 | 0.210 |
Why?
|
| Calcaneus | 1 | 2003 | 8 | 0.210 |
Why?
|
| Foot Diseases | 1 | 2003 | 23 | 0.210 |
Why?
|
| Infant | 7 | 2021 | 13032 | 0.190 |
Why?
|
| Brucella melitensis | 1 | 2002 | 8 | 0.190 |
Why?
|
| Brucellosis | 1 | 2002 | 19 | 0.190 |
Why?
|
| Levofloxacin | 1 | 2022 | 47 | 0.180 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2002 | 34 | 0.180 |
Why?
|
| Dermatomycoses | 1 | 2021 | 18 | 0.180 |
Why?
|
| Mucormycosis | 1 | 2021 | 32 | 0.170 |
Why?
|
| Osteomyelitis | 1 | 2003 | 213 | 0.170 |
Why?
|
| Humans | 19 | 2025 | 131930 | 0.170 |
Why?
|
| Infant, Newborn | 7 | 2021 | 8535 | 0.170 |
Why?
|
| Staphylococcal Infections | 3 | 2015 | 569 | 0.160 |
Why?
|
| Diarrhea | 1 | 2022 | 329 | 0.160 |
Why?
|
| Infection Control | 3 | 2021 | 157 | 0.150 |
Why?
|
| Intensive Care Units, Neonatal | 4 | 2011 | 337 | 0.140 |
Why?
|
| Risk Factors | 4 | 2025 | 10893 | 0.140 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 1176 | 0.140 |
Why?
|
| Staphylococcus aureus | 2 | 2015 | 479 | 0.140 |
Why?
|
| Adolescent | 5 | 2021 | 20524 | 0.130 |
Why?
|
| Angiostrongylus cantonensis | 1 | 2016 | 9 | 0.130 |
Why?
|
| Strongylida Infections | 1 | 2016 | 15 | 0.130 |
Why?
|
| Critical Illness | 1 | 2021 | 617 | 0.130 |
Why?
|
| Retrospective Studies | 6 | 2022 | 17345 | 0.130 |
Why?
|
| Child, Preschool | 4 | 2021 | 14715 | 0.130 |
Why?
|
| Logic | 1 | 2015 | 9 | 0.120 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 680 | 0.120 |
Why?
|
| Chlorhexidine | 1 | 2015 | 47 | 0.120 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2015 | 67 | 0.120 |
Why?
|
| Models, Educational | 1 | 2015 | 73 | 0.120 |
Why?
|
| Cystic Fibrosis | 1 | 2017 | 264 | 0.110 |
Why?
|
| Follow-Up Studies | 2 | 2022 | 5394 | 0.100 |
Why?
|
| Career Choice | 1 | 2015 | 160 | 0.100 |
Why?
|
| Pandemics | 1 | 2021 | 1185 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 1552 | 0.100 |
Why?
|
| Male | 10 | 2021 | 64846 | 0.100 |
Why?
|
| Female | 10 | 2021 | 70607 | 0.090 |
Why?
|
| Faculty, Medical | 1 | 2015 | 277 | 0.090 |
Why?
|
| Bedding and Linens | 1 | 2011 | 7 | 0.090 |
Why?
|
| Hospital Design and Construction | 1 | 2011 | 11 | 0.090 |
Why?
|
| Bacillus | 1 | 2011 | 37 | 0.090 |
Why?
|
| Genotype | 1 | 2017 | 2703 | 0.080 |
Why?
|
| Young Adult | 2 | 2021 | 9929 | 0.080 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 1966 | 0.070 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2008 | 41 | 0.070 |
Why?
|
| Candida albicans | 1 | 2008 | 90 | 0.070 |
Why?
|
| Neoplasms | 1 | 2022 | 2953 | 0.070 |
Why?
|
| Mycoses | 1 | 2008 | 117 | 0.060 |
Why?
|
| Premature Birth | 1 | 2011 | 418 | 0.060 |
Why?
|
| Infant, Very Low Birth Weight | 2 | 2005 | 176 | 0.060 |
Why?
|
| Serratia Infections | 1 | 2006 | 6 | 0.060 |
Why?
|
| Serratia marcescens | 1 | 2006 | 11 | 0.060 |
Why?
|
| Methicillin Resistance | 1 | 2004 | 118 | 0.050 |
Why?
|
| Gestational Age | 2 | 2005 | 1226 | 0.050 |
Why?
|
| Cohort Studies | 4 | 2008 | 5143 | 0.050 |
Why?
|
| Infant, Premature, Diseases | 1 | 2004 | 252 | 0.050 |
Why?
|
| Rhizopus | 1 | 2021 | 10 | 0.050 |
Why?
|
| Incidence | 2 | 2008 | 3362 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2006 | 1226 | 0.040 |
Why?
|
| Doxycycline | 1 | 2002 | 121 | 0.040 |
Why?
|
| Rifampin | 1 | 2002 | 120 | 0.040 |
Why?
|
| Antibodies, Bacterial | 1 | 2002 | 406 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2006 | 12996 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2015 | 382 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 2 | 2015 | 827 | 0.040 |
Why?
|
| Proteus mirabilis | 1 | 2016 | 12 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2016 | 98 | 0.030 |
Why?
|
| Meningitis | 1 | 2016 | 100 | 0.030 |
Why?
|
| Mupirocin | 1 | 2015 | 20 | 0.030 |
Why?
|
| Electrophoresis, Gel, Pulsed-Field | 1 | 2015 | 93 | 0.030 |
Why?
|
| Prednisone | 1 | 2016 | 252 | 0.030 |
Why?
|
| Multilocus Sequence Typing | 1 | 2015 | 62 | 0.030 |
Why?
|
| Eosinophilia | 1 | 2016 | 105 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2002 | 1303 | 0.030 |
Why?
|
| Program Development | 1 | 2015 | 190 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2015 | 176 | 0.030 |
Why?
|
| Medicine | 1 | 2015 | 106 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2008 | 1439 | 0.020 |
Why?
|
| Leadership | 1 | 2015 | 246 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 322 | 0.020 |
Why?
|
| Coagulase | 1 | 2004 | 23 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3852 | 0.010 |
Why?
|
| Drug Resistance, Multiple | 1 | 2004 | 54 | 0.010 |
Why?
|
| Staphylococcus | 1 | 2004 | 68 | 0.010 |
Why?
|
| Gentamicins | 1 | 2004 | 87 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2004 | 157 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 1835 | 0.010 |
Why?
|
| Age of Onset | 1 | 2004 | 626 | 0.010 |
Why?
|
| Survival Rate | 1 | 2008 | 2183 | 0.010 |
Why?
|
| Hypotension | 1 | 2004 | 183 | 0.010 |
Why?
|
| Hypoxia | 1 | 2004 | 259 | 0.010 |
Why?
|
| Vancomycin | 1 | 2004 | 222 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2004 | 842 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2008 | 3710 | 0.010 |
Why?
|
| Middle Aged | 1 | 2015 | 28893 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 34908 | 0.010 |
Why?
|
| Adult | 1 | 2015 | 31506 | 0.010 |
Why?
|